NCT06943950View on ClinicalTrials.gov

A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

April 28, 2027

Study Completion Date

June 30, 2027

Conditions
Moderate to Severe Plaque Psoriasis
Interventions
DRUG

SYHX1901

Administered orally, once daily (QD)

Sponsors
All Listed Sponsors
lead

CSPC Ouyi Pharmaceutical Co., Ltd.

INDUSTRY

NCT06943950 - A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter